Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
Andreas MeiselDjillali AnnaneTuan VuRenato MantegazzaMasahisa KatsunoRasha AguzziGlen FrickLaura GaultJames F Howardnull nullPublished in: Journal of neurology (2023)
gov identifier: NCT03920293; EudraCT: 2018-003243-39.